A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma.

Trial Profile

A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs MORAB 028 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Morphotek
  • Most Recent Events

    • 16 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 06 Oct 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 13 Sep 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top